Sirtex Medical Ltd. | Cash Flow

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Net Income before Extraordinaries
23,868.00
40,345.00
53,582.00
26,257.00
41,469.00
Depreciation, Depletion & Amortization
1,591.00
2,379.00
6,567.00
6,916.00
3,376.00
Other Funds
1,747.00
2,826.00
2,322.00
95,280.00
13,302.00
Funds from Operations
32,689.00
48,974.00
68,270.00
49,766.00
51,950.00
Changes in Working Capital
518.00
3,000.00
3,059.00
6,206.00
4,069.00
Net Operating Cash Flow
32,171.00
51,974.00
65,211.00
55,972.00
56,019.00
Capital Expenditures
25,037.00
22,815.00
20,914.00
22,940.00
795.00
Sale of Fixed Assets & Businesses
-
201.00
137.00
-
-
Purchase/Sale of Investments
2,000.00
22,000.00
34,000.00
18,000.00
10,000.00
Net Investing Cash Flow
23,037.00
44,614.00
54,777.00
4,940.00
9,205.00
Cash Dividends Paid - Total
6,733.00
7,914.00
11,432.00
17,306.00
16,726.00
Net Financing Cash Flow
6,733.00
7,914.00
11,432.00
20,179.00
43,853.00
Net Change in Cash
2,401.00
554.00
916.00
29,324.00
19,547.00
Free Cash Flow
25,982.00
50,282.00
63,493.00
54,733.00
55,346.00
Deferred Taxes & Investment Tax Credit
5,483.00
3,424.00
5,799.00
26,173.00
6,197.00
Change in Capital Stock
-
-
-
2,873.00
27,127.00
Exchange Rate Effect
-
-
82.00
1,529.00
1,824.00

About Sirtex Medical

View Profile
Address
101 Miller Street
North Sydney New South Wales (NSW) 2060
Australia
Employees -
Website http://www.sirtex.com
Updated 09/14/2018
Sirtex Medical Ltd. engages in the research, commercial development, manufacture, and distribution of liver cancer treatments. It offers targeted radiation therapy known as SIR-Spheres Y-90 resin microspheres. Its clinical programs include SIRFLOX, FOXFIRE/FOXFIRE Global, SARAH, SIRveNIB, and SORAMIC.